Products
Online Inquiry
Our Products Cannot Be Used As Medicines Directly For Personal Use.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
BEZ235 (NVP-BEZ235)
Cat No.
CEI-0140
Description
BEZ235 (NVP-BEZ235) can inhibit Thr308-P-Akt, Ser473-P-Akt and mTOR with IC50 of 29 nM, 8 nM and 6.5 nM.
CAS No.
915019-65-7
Molecular Weight
469.55
Purity
>99%
Storage
2 years at -20centigrade Powder
Targets
Thr308-P-Akt, Ser473-P-Akt, mTOR
Molecular Formula
C30H23N5O
Chemical Name
2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile
Solubility
DMSO 1 mg/mL Water
In vitro
NVP-BEZ235 is an ATP competitor that potently and reversibly reduces the kinase activity of both p110 and mTOR. NVP-BEZ235 inhibits several PI3K pathway effectors, among them the serine/threonine-specific protein kinase Akt, the ribosomal protein S6, and the eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) and induces nuclear translocation of forkhead transcription factor FKHRL1 (FOXO3a). The reported IC 50 s for Thr308-P-Akt and Ser473-P-Akt are 29 and 8 nmol/L, respectively, and 6.5 nmol/L for mTOR.
In vivo
The antitumor activity of NVP-BEZ235 was also evaluated in vivo using a xenograft model of BT474-derived cells overexpressing either the p110- a H1047R oncogenic mutation or an empty vector (mock control). NVP-BEZ235 significantly reduced tumor growth of both H1047R and empty vector control xenografts.
Download
Download Datasheet